A degradable and foldable bio-amnion composite repair scaffold

Abstract

The invention discloses a degradable foldable bio-amniotic membrane composite repair bracket, which comprises a tubular body with a through hole extending axially, an elastic balloon at the front end of the tubular body, and a single end connected to the tubular body. A one-way valve, where the one-way valve closes the through hole, the outer surface of the elastic balloon is covered with a foldable mesh-shaped polylactic acid stent, and the outer surface of the foldable mesh-shaped polylactic acid stent is covered There is biological amniotic membrane, the mesh of the foldable mesh-shaped polylactic acid scaffold has several micropores, and some of the micropores are filled with biological amniotic membrane powder; in the initial state, the elastic balloon, the foldable mesh tubular polylactic acid The lactic acid stent and biological amniotic membrane are compressed into a tight state; in use, after the implant is pressurized and expanded, it can conform to the lacrimal duct / uterine cavity to form a tubular or drop-like shape or other body cavities to adapt to the spatial shape.

Description

technical field [0001] The invention relates to the technical field of biomedicine, in particular to a multipurpose and degradable foldable bio-amniotic membrane composite repair bracket. Background technique [0002] Lacrimal duct obstruction diseases (LDOD) refer to a class of diseases caused by various reasons, characterized by lacrimal duct obstruction (lacrimal duct stenosis and / or occlusion) and epiphora as the main clinical manifestation. According to incomplete statistics, LDOD accounts for about 3% of ophthalmology outpatients, and is a common and frequently-occurring disease in ophthalmology. Lacrimal duct obstruction may occur in any part of the lacrimal duct, among which lacrimal canalicular obstruction is a relatively common type in LDOD, and its incidence rate accounts for about 16% to 25% of LDOD. There are many causes of canaliculus obstruction, including inflammation, trauma, congenital abnormalities, drugs, systemic diseases, iatrogenic injuries, and degen...

AI Technical Summary

Problems solved by technology

[0017] In summary, the current treatment of lacrimal duct obstruction, intrauterine adhesions and related diseases mainly has the following common problems: ①Simple non-surgical dredging treatment for lacrimal duct obstruction or intrauterine adhesions after intrauterine adhesion resection, due to lack of support The support effect of the substance on the wall of the lacrimal duct / uterine cavity, the closure of the lacrimal duct / uterine cavity wall, and the pathological repair of the wound will occur during the wound healing process, and granulation tissue or the lacrimal duct / uterine cavity wall will be formed later Scar contraction and adhesions are formed; ② non-degradable material stents, as foreign bodies, stimulate the lacrimal duct / uterine cavity mucosa, and even cause rejection in severe cases; ③ improper fixation of the stent after insertion into the lacrimal duct / uterine cavity causes slippage; ④ Implantation of stents will cause persistent expansion and compression of the tube wall, which is not conducive to the regression of inflammation and edema on the inner wall and the repair of the mucosa of the tube wall, hindering the normal repair of tissues, and can cause chronic inflammatory reactions on the wall of the lacrimal canaliculus / uterine cavity. In severe cases It can stimulate the mucosa to form granulation tissue and wrap the implanted stent, which will make it difficult to remove the stent and even cause secondary trauma; The active substance or drug enters the tissue to exert its effect

Images